Efficacy of Combination Immunotherapy in Patients With Metastatic Colorectal Cancer

First Affiliated Hospital of Zhejiang University97 enrolled

Overview

Immunotherapy improved efficacy and survival in selective patients with metastatic colorectal cancer (mCRC), however, limited data revealed the landscape of immunotherapy efficacy. What's more, potential markers have not been comprehensively evaluated to identify responding patients to further improve efficacy.The investigators conducted a single-arm study to investigate the efficacy of combination immunotherapy in patients with mCRC, and the combined regimen is determined by the physician in charge.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Colorectal Cancer

Interventions

CombinationsDRUG

PD-1 inhibitor-based combinaiton treatment

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * patients who had both baseline measurable lesion(s) and at least one post-baseline radiological disease reassessment * patients with identified genomic status Exclusion Criteria: * patients who received immune monotherapy * patients who stopped treatment for any reason without identified response assessment.

Locations (1)

The First Affiliated Hospital, Zhejiang University School of Medicine

Hangzhou, Zhejiang, China

Outcomes

Primary Outcomes

Durable clinical benefit

Rate of patients who acheived CR or PR or SD that lasted more than 6 months

Time frame: immediately after the intervention

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.